Mark F. Sasse retweeted
What are the benefits of #IVUS-guided #DCB angioplasty in de novo lesions? 🤔
Check out the results of the ULTIMATE III trial in this issue of #JACCINT: bit.ly/3Whw0TJ
Mark F. Sasse retweeted
In patients undergoing valve-in-valve (ViV) interventions for failed surgical bioprosthetic valves, performing bioprosthetic valve fracture (BVF) after transcatheter heart valve (THV) implantation, compared to BVF performed before THV implantation or no BVF, resulted in better immediate hemodynamic performance and sustained valve function without long-term trade-offs in THV performance or structural valve damage, as demonstrated in bench studies simulating up to 5 years of valve wear.#EIJBestOf
@David_Meier_ @sellers_steph
👉ow.ly/hlwg50Sy4gM
Mark F. Sasse retweeted
You may have heard of the "5-6-7-8" rule for LM-LAD-LCx stent MSAs to reduce long term MACE, but this new study in @CircIntv suggests that bigger MSAs are needed.
A new "6-8-12" rule?
ahajournals.org/doi/10.1161/…).
Mark F. Sasse retweeted
Patient was referred to our centre for CABG due to significant proximal and mid LAD disease. Review of diagnostic angio showed this. What do you think might have happened here
Mark F. Sasse retweeted
Anticoagulation with #DOACs vs. #VKAs in patients with left #ventricular thrombus: a new meta-analysis just published in #EHJPharmacotherapy 💊 bit.ly/3yVn3Gi
@EditorEHJCVP @FeliceGragnano @DrErikGrove @GianluSava @jpkaski
Mark F. Sasse retweeted
Contemporary issues of percutaneous coronary intervention in heavily calcified chronic total occlusions: an expert review from the European CTO Club. #EIJBestOf ow.ly/8qaG50OGpNo
Mark F. Sasse retweeted
🔴🔥Simple diagnostic criteria for HFpEF
✅A score of 6 or more is highly suggestive of HFpEF!
jacc.org/doi/epdf/10.1016/j.…
#cardiovascular #medx #MedEd #CardioTwitter #CardioEd #Meded #medEd #cardiotwiteros #MedX #MedTwitter #cardiotwitter #medtwitterWhat #medical #cardiox
Mark F. Sasse retweeted
Everything about calcified nodules!
authors.elsevier.com/a/1j9qM…
@JACCJournals
@DoosupShin
@jcspratt
@MaeharaAkiko
@ColletCarlos
@EmanueleBarba13
@FlavioRibichini
@NievesGonzalo1
@koshiro__Sakai
@GreggWStone
@ESHLOF
@drallenj
@OPCILive
@StFrancis_LI
@crfheart
@djc795
@FernanOCT
Mark F. Sasse retweeted
In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, PCI did not reduce the incidence of death or hospitalization for heart failure (HHF). Similarly, in a recent prespecified secondary analysis, PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up jacc.org/doi/10.1016/j.jchf.… @JACCJournals
Mark F. Sasse retweeted
Warning: for novice US DCB users! DCB are not non compliant! Here is a perforation i had with a 3.5 DCB after taking it to its nominal 14 Bar pressure( it grew to 4) after an uneventful NC PTCA using NC quantum 3.5/15 at 28 Bar!
Watch ur size chart!
Mark F. Sasse retweeted
Do you "wedge" the PA catheter in the CICU because you don't trust the surrogate PA diastolic?
Compelling safety reasons to avoid doing this.
A new study in @JCardFail validating the use of PA diastolic for most patients with left-sided predominant CS.
onlinejcf.com/article/S1071-…
Very important question!
We’re coming closer to enrollment completion for the #STAR trial led by Taishi Hirai & @KateKearney4.
Hopefully it’ll confirm the safety and efficacy of a 2-step #CTO recanalization in case of impending failure or to avoid risky epicardial collaterals, like this one 👇🏻.
Mark F. Sasse retweeted
Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest tctmd.com/news/obstructive-c… thx @michaelTCTMD for asking me to chime into this timely question @TCTMD @mmamas1973
Mark F. Sasse retweeted
Update data from a post hoc secondary analysis of the #STRONG-HF trial
📍In 515 patients, over 90% received medium-to-high doses of #GDMT just 2 weeks post-discharge.
📍⤵️ readmission and death rates in 6 months + better #QoL
📍Rapidly optimizing doses of 4 pillars HF meds was feasible and safe in most patients, and crucial for better outcomes in #AHF patients.
jamanetwork.com/journals/jam… @JAMACardio #HeartFailure
Mark F. Sasse retweeted
Amiodarone for atrial fibrillation: a dead man walking? Read the latest editorial in #EHJ.
doi.org/10.1093/eurheartj/eh…
#amiodarone #AF ##cardiotwitter @ESC_Journals @escardio
Mark F. Sasse retweeted
Unexpectedly “fished”🐠 this out of the LV apex during Impella CP removal. Patient recovering from large anterior MI with apical akinesis. Incredibly lucky; no clinical signs of embolization! 🍀 😬@SandeepNathanMD @Babar_Basir @ShashankSinhaMD @VorovichHeartMD @BurkhoffMd @NavinKapur4 @Abiomed @TheRealDoctorOs @SGuptaMD
Mark F. Sasse retweeted
An excellent way to cross retrogradely is to telescope an angled glide catheter through 6F and cross it using a straight wire. Learned from @tjsimard. @benhibbertMDPhD
Mark F. Sasse retweeted
Do you know the presentation, management, and outcomes of very late sinus sequestration in native aortic annuli? If not, learn about it in #JACCCaseReports: bit.ly/3ZPN4Ai
#TAVI #TAVR #CardioTwitter
































